Enveric Biosciences Files 8-K
Ticker: ENVB · Form: 8-K · Filed: Mar 19, 2024 · CIK: 890821
| Field | Detail |
|---|---|
| Company | Enveric Biosciences, Inc. (ENVB) |
| Form Type | 8-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Disclosure
TL;DR
Enveric Biosciences filed a routine 8-K, no major news.
AI Summary
Enveric Biosciences, Inc. filed an 8-K on March 19, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates Enveric Biosciences is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting disclosures and exhibits, with no indication of significant new risks or events.
Key Players & Entities
- Enveric Biosciences, Inc. (company) — Registrant
- 0001493152-24-010419 (filing_id) — Accession Number
- March 19, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the company filing this report?
The exact name of the company is Enveric Biosciences, Inc.
On what date was this report filed?
The report was filed on March 19, 2024.
In which state was Enveric Biosciences, Inc. incorporated?
Enveric Biosciences, Inc. was incorporated in Delaware.
What is the principal executive office address for Enveric Biosciences, Inc.?
The principal executive office address is 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.
Filing Stats: 601 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-19 07:00:16
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share ENVB The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 19KB
- image_001.jpg (GRAPHIC) — 26KB
- 0001493152-24-010419.txt ( ) — 268KB
- envb-20240319.xsd (EX-101.SCH) — 3KB
- envb-20240319_lab.xml (EX-101.LAB) — 33KB
- envb-20240319_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 19, 2024 ENVERIC BIOSCIENCES, INC. By: /s/ Joseph Tucker Joseph Tucker, Ph.D. Chief Executive Officer